Results 1 to 10 of about 49,177 (212)
Tardive Dyskinesia and Treatment Approaches [PDF]
Psikiyatride Güncel Yaklaşımlar, 2018 Tardive dyskinesia is an iatrogenic movement disorder with an incompletely determined etiology. Involuntary movements can effect oral, lingual, facial, corporal muscles and can be permanent. Tardive dyskinesia is one of the most important side effects of
Mehmet Emin Demirkol +3 more
doaj +4 more sources
Tardive Dyskinesia in Patients Receiving Continuous Versus Intermittent Oral Metoclopramide: A Retrospective Real World Study. [PDF]
Neurogastroenterol MotilContinuous MCP dosing was associated with higher TD prevalence and earlier onset. Intermittent dosing, despite longer cumulative exposure, was associated with lower TD risk. These findings suggest that intermittent regimens may offer a safer MCP therapeutic strategy. ABSTRACT Background Tardive dyskinesia (TD) is an often irreversible movement disorder
Russo P, Nathan R, Camilleri M.
europepmc +2 more sources
Response to [Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia]. [PDF]
Psychiatry Clin NeurosciThis article relates to Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia.
Hsu TW, Tsai CK, Liang CS.
europepmc +2 more sources
Adverse outcomes between VMAT2 and anticholinergics in tardive dyskinesia: A target trial emulation. [PDF]
Psychiatry Clin NeurosciAim Vesicular monoamine transporter 2 (VMAT2) inhibitors have been approved for the treatment of tardive dyskinesia (TD), whereas anticholinergic agents are still widely used for this condition. This study aimed to compare the risk of major clinical adverse outcomes among patients with TD treated with VMAT2 inhibitors versus anticholinergic agents ...
Hsu TW +13 more
europepmc +2 more sources
Refractory tardive dyskinesia in the critical care setting: A case report of successful use of phenobarbital [PDF]
SAGE Open Medical Case ReportsTardive dyskinesia is a hyperkinetic movement disorder most often induced by chronic antipsychotic use. It can be challenging to treat, particularly when symptoms persist despite standard therapies such as vesicular monoamine transporter 2 inhibitors. We
Abdelrahman S. Abdalla +4 more
doaj +2 more sources
Co‐Expression of Tardive Dyskinesia and Drug‐Induced Parkinsonism in Rats Chronically Treated With Haloperidol [PDF]
Neuropsychopharmacology ReportsAim We aimed to create a rat model of drug‐induced parkinsonism and tardive dyskinesia by chronic administration of haloperidol and examine the expression of direct and indirect pathway markers in the striatum of the model rats.
Iku Kinoshita +7 more
doaj +2 more sources
Treatment of tardive dyskinesias with vitamin E: A case series
European Psychiatry, 2023 Introduction Tardive dyskinesia is usually persistent, irreversible involuntary movement of the tongue, lips, face, trunk and extremities in patients taking long-term dopaminergic antagonist drugs.
B. Senol +3 more
doaj +1 more source
Metoclopramide in Gastroparesis: Its Mechanism of Action and Safety Profile
Gastrointestinal Disorders, 2023 Metoclopramide has been the cornerstone of gastroparesis management for the past 40 years as it is the only FDA-approved medication for gastroparesis. Other medications such as erythromycin and domperidone have been used off-label with variable efficacy.
M Ammar Kalas +4 more
doaj +1 more source
Бюллетень сибирской медицины, 2015 The purpose of the present work was to study the clinical features and risk factors of tardive dyskinesia among the schizophrenia patients who durably receive the antipsychotic therapy.
Ye. G. Kornetova +4 more
doaj +1 more source
Consilium Medicum, 2021 Tardive dyskinesia is a group of hyperkinetic and hypokinetic movement disorders, following the administration of dopamine receptor-blocking drugs. The severity of these syndromes varies from soft forms to the development of life-degrading situations ...
Violetta A. Tolmacheva
doaj +1 more source